Syndax Pharmaceuticals(NASDAQ) SNDX

Syndax Pharmaceuticals, Inc. makes medicines for specific cancers. These drugs help patients when standard treatments fail. The company treats blood cancers and transplant complications.

Medicines for Targeted Care

• Revuforj: Medicine that blocks cancer-growing proteins in patients with leukemia that has returned or stopped responding to treatment; earned $54.7 million in net revenue for the second quarter of 2026.
• Niktimvo: Antibody used when transplanted cells attack a patient’s body after a transplant; generated $18.1 million in collaboration revenue for the three months ended June 30, 2026.
• Experimental Pipeline: Growing set of drug candidates for lung cancer and bone marrow disorders; currently undergoing clinical testing to determine safety and effectiveness.

Milestones in Growth

• Launched Revuforj in November 2024 following its first approval by the FDA.
• Received FDA approval for Niktimvo in August 2024 to treat transplant complications.
• Announced the addition of two new drug candidates to the pipeline in July 2026.
• Issued $250.0 million in convertible notes in June 2026 to raise capital for operations.

Innovation and Partner Success

Syndax works with partners like Incyte to share the costs and profits of selling new drugs. The company focuses on first-in-class therapies, which are medicines that use a unique scientific method to treat diseases that other drugs cannot reach.

Measuring Financial Progress

• Total revenue was $72.8 million for the three months ended June 30, 2026, up from $38.0 million in the same period of 2025.
• Revuforj net revenue reached $54.7 million in the second quarter of 2026, which was a 91% increase year over year.
• Net loss was $92.0 million for the six months ended June 30, 2026, compared to a net loss of $156.7 million for the same period in 2025.
• Cash, cash equivalents, and investments totaled $575.1 million as of June 30, 2026.
• The company had an accumulated deficit of $1.6 billion as of June 30, 2026.

The Evolution Summary

Syndax has moved from a research firm into a commercial business with two approved products on the market. It continues to develop new cancer treatments while managing the high costs and risks associated with medical trials.